₹2,850.2
▼ -38.42 -1.33%
As of 27 Jul 2026 · delayed
NSE Listed
RPG Life Sciences Ltd. (RPGLIFE)
Volume: 16,148Avg Vol 1W: 21,832.8Avg Vol 1M: 54,930.752W Range:₹1,733₹3,082
Key Ratios
Checked 2d agoMarket Cap₹4,841 Cr
Current Price₹2,850.2
Previous Close₹2,888.62
High / Low (52w)₹3,082 / ₹1,733
Volume16,148
Avg Vol (1W)21,832.8
Avg Vol (1M)54,930.7
Stock P/E161.89
Book Value₹366.05
Dividend Yield1.1%
ROE19%
ROA14.5%
Revenue (TTM)₹733 Cr
Revenue Growth—
Profit Margin16.3%
Total Debt₹20 Cr
Shares Outstanding2 Cr
Face Value₹8
EPS (TTM)₹18.08
P/B8
Debt / Equity0.03
50 DMA₹2,447.49
200 DMA₹2,228.59
Day change-1.33%
Price Chart
₹2,850.2▲ 26.12% · 1Y
2025-07-292026-07-27
20-day avg volume: 55K shares
Pros
- Healthy return on equity of 19.0%.
- Company is almost debt-free.
Cons
- Stock trades at a high P/E of 162.
Quarterly Results
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹172 Cr | ₹173 Cr | ₹143 Cr | ₹169 Cr | ₹182 Cr | ₹180 Cr | ₹177 Cr | ₹196 Cr |
| EBITDA | ₹43 Cr | ₹47 Cr | ₹25 Cr | ₹36 Cr | ₹38 Cr | ₹38 Cr | ₹39 Cr | ₹42 Cr |
| Net Profit | ₹4 Cr | ₹35 Cr | ₹117 Cr | ₹26 Cr | ₹37 Cr | ₹22 Cr | ₹30 Cr | ₹31 Cr |
| EPS | 2.54 | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹143 Cr | ₹666 Cr | ₹169 Cr | ₹182 Cr | ₹180 Cr | ₹177 Cr | ₹733 Cr | ₹196 Cr |
| EBITDA | ₹25 Cr | ₹151 Cr | ₹36 Cr | ₹38 Cr | ₹38 Cr | ₹39 Cr | ₹151 Cr | ₹42 Cr |
| Net Profit | ₹117 Cr | ₹183 Cr | ₹26 Cr | ₹37 Cr | ₹22 Cr | ₹30 Cr | ₹115 Cr | ₹31 Cr |
| EPS | — | 110.8 | — | — | — | — | 69.64 | — |
Balance Sheet
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹267 Cr | ₹303 Cr | ₹345 Cr | ₹419 Cr | ₹513 Cr | ₹658 Cr | ₹793 Cr |
| Total Liabilities | ₹90 Cr | ₹87 Cr | ₹89 Cr | ₹112 Cr | ₹138 Cr | ₹127 Cr | ₹188 Cr |
| Equity | ₹177 Cr | ₹216 Cr | ₹256 Cr | ₹308 Cr | ₹375 Cr | ₹531 Cr | ₹605 Cr |
| Total Debt | ₹2 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | — | — | — |
Cash Flow
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | ₹67 Cr | ₹84 Cr | ₹116 Cr | ₹124 Cr | ₹131 Cr | ₹94 Cr |
| Investing | ₹-8 Cr | ₹-35 Cr | ₹-106 Cr | ₹-79 Cr | ₹-42 Cr | ₹86 Cr |
| Financing | ₹-10 Cr | ₹-14 Cr | ₹-17 Cr | ₹-20 Cr | ₹-27 Cr | ₹-21 Cr |
| Free Cash Flow | ₹67 Cr | ₹84 Cr | ₹116 Cr | ₹124 Cr | ₹131 Cr | ₹94 Cr |
Shareholding
Promoter 72.95% Institutions 9.63% Public 17.42%
Efficiency & Working Capital
ROCE32.3%
Interest Coverage88.1
Dividend Payout—
Debtor Days60 d
Inventory Days64 d
Payable Days50 d
Cash Conversion Cycle74 d
Working Capital Days124 d
Shareholding Details
As of 2026-06-30
Promoter73%
FII1%
DII8.7%
Institutions9.6%
Public17.4%
Promoter Pledge0%
No. of Shareholders23,886
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 72.8% | 72.8% | 72.8% | 72.8% | 72.8% | 73% | 73% | 73% | 73% | 73% | 73% | 73% |
| FIIs | 0.5% | 0.6% | 0.9% | 1.1% | 1.3% | 1.3% | 1.5% | 1.3% | 1.1% | 1% | 0.9% | 1% |
| DIIs | 3.6% | 3.8% | 4.2% | 4.6% | 5.5% | 6.1% | 6.1% | 6.5% | 6.7% | 7% | 7.4% | 8.7% |
| Public | 23.1% | 22.8% | 22.1% | 21.4% | 20.4% | 19.7% | 19.5% | 19.2% | 19.2% | 19% | 18.7% | 17.4% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 21,088 | 21,866 | 22,137 | 22,232 | 23,481 | 24,891 | 24,867 | 25,832 | 26,657 | 25,905 | 25,282 | 23,886 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202603 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Nucleus Life Trust (mr. Harsh Vardhan Goenka Is A Trustee) | Shareholding of Promoter and Promoter Group | 53.9% | 89,20,831 |
| Ektara Enterprises Llp | Shareholding of Promoter and Promoter Group | 15.6% | 25,75,494 |
| Clarus Capital I | Public Shareholding | 5.6% | 9,23,957 |
| Stel Holdings Limited | Shareholding of Promoter and Promoter Group | 3.2% | 5,25,369 |
| Authum Investment And Infrastructure Limited | Public Shareholding | 2% | 3,33,474 |
| Harshvardhan Goenka | Shareholding of Promoter and Promoter Group | 0.2% | 26,915 |
| Mala Goenka | Shareholding of Promoter and Promoter Group | 0.1% | 8,747 |
| Carniwal Investments Limited | Shareholding of Promoter and Promoter Group | 0% | 6,500 |
| Instant Holdings Limited | Shareholding of Promoter and Promoter Group | 0% | 598 |
| Summit Securities Limited | Shareholding of Promoter and Promoter Group | 0% | 398 |
| Chattarpati Apartments Llp | Shareholding of Promoter and Promoter Group | 0% | 362 |
| Atlantus Dwellings And Infrastructure Llp | Shareholding of Promoter and Promoter Group | 0% | 10 |
| Malabar Coastal Holdings Llp | Shareholding of Promoter and Promoter Group | 0% | 10 |
| Sofreal Mercantrade Pvt Ltd | Shareholding of Promoter and Promoter Group | 0% | 10 |
| Swallow Associates Llp | Shareholding of Promoter and Promoter Group | 0% | 10 |
| Vayu Associates Llp | Shareholding of Promoter and Promoter Group | 0% | 10 |
| Citibank N A Jt Ac Sakina Asgarali Morbiwala Nooruddin A Morbiwala | Public Shareholding | 0% | 150 |
| Rg Family Trust (mr. Anant Vardhan Goenka Is A Trustee) | Shareholding of Promoter and Promoter Group | 0% | 10 |
| Ishaan Goenka Trust (mr. Harsh Vardhan Goenka Is A Trustee) | Shareholding of Promoter and Promoter Group | 0% | 10 |
| Navya Goenka Trust (mr. Harsh Vardhan Goenka Is A Trustee) | Shareholding of Promoter and Promoter Group | 0% | 10 |
| Secura India Trust (mr. Harsh Vardhan Goenka Is A Trustee ) | Shareholding of Promoter and Promoter Group | 0% | 2 |
| Avg Family Trust (mr. Anant Vardhan Goenka Is Atrustee ) | Shareholding of Promoter and Promoter Group | 0% | 10 |
| Prism Estates Trust (mr. Harsh Vardhan Goenka Is A Trustee ) | Shareholding of Promoter and Promoter Group | 0% | 1 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| H V Goenka | Chairman & Non Executive Dir. | 2026 |
| Manoj K Maheshwari | Non-Exec & Non-Independent Dir | 2026 |
| Zahabiya Habil Khorakiwala | Independent Non Exe. Director | 2026 |
| Bhaskar Vemban Iyer | Independent Non Exe. Director | 2026 |
| Sachin Nandgaonkar | Independent Non Exe. Director | 2026 |
| Rajat Bhargava | Non-Exec & Non-Independent Dir | 2026 |
| Anil Matai | Independent Non Exe. Director | 2026 |
| Hiten Kotak | Independent Non Exe. Director | 2026 |
| RADHIKA GUPTA | Independent Non Exe. Director | 2026 |
| Vasundhara Patni | Non-Exec & Non-Independent Dir | 2026 |
| Yugal Sikri | Non-Exec & Non-Independent Dir | 2026 |
| ASHOK NAIR | Executive Director & MD | 2026 |
| Pratit Samdani | Independent Non Exe. Director | 2026 |
| Rajesh Shirambekar | Company Secretary / Legal Head | 2026 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| manufacturing and marketing of phar | ₹0 Cr | — |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| India | ₹483 Cr | 68.3% |
| Outside India | ₹224 Cr | 31.7% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹8 | 15 | 13 | 13 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-07-28 | Board Meetings | — |
| forthcoming | 2026-07-09 | Dividend (24/- per share) | Final |
| dividend | 2026-07-09 | ₹24 (300%) | Final |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2026 | 35 | 0 | 0 | 8 | 17 | 60 |
| 2026 | 35 | 0 | 0 | 0 | 1 | 35 |
| 2026 | 0 | 0 | 0 | 8 | 16 | 24 |
Insider / Designated-Person Trades
30 recent disclosure(s)
Nucleus Life Trust RevisedAcquisition · 3,048
Nucleus Life Trust RevisedAcquisition · 4,412
Nucleus Life Trust RevisedAcquisition · 306
Nucleus Life Trust RevisedAcquisition · 1,859
Nucleus Life TrustAcquisition · 1,800
Nucleus Life TrustAcquisition · 10
Company Information
🌐 www.rpglifesciences.com ↗
📍 RPG House, 463 Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search